We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

Pfizer has appointed former Patrizia Cavazzoni, MD, former director of the FDA's Center for Drug Evaluation and Research, as its new chief medical officer, Bloomberg reported Feb. 24. Dr. Cavazzoni, ...

Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...

HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...